

Appointment of Chief Technology Officer

Genetic Signatures [ASX:GSS] (“GSS” or “the Company”), a global molecular diagnostics company announces that it has today appointed Dr Susanne Pedersen to the role of Chief Technology Officer (CTO).

Dr Pedersen has a PhD in molecular biology and over 25 years of experience in the development and commercialisation of molecular *in vitro* diagnostic (IVD) products. Dr Pedersen was a co-founder of Clinical Genomics Pty Ltd where, as Vice President of Science & Innovation, she led the discovery, development and commercialisation of Colvera™ – Australia’s first CLIA-accredited liquid biopsy for colorectal cancer. Through this role, Dr Pedersen established in-depth technical expertise in the discovery and validation of clinically relevant biomarkers (DNA, RNA and proteins) as well as extensive experience in the regulatory, clinical and quality requirements for developing commercial molecular IVD products.

Dr Pedersen will have primary responsibility for managing the development of Genetic Signatures’ technology and molecular diagnostic products. This will include ongoing initiatives to optimise and streamline Genetic Signature’s **3base**® technology platform and workflow, the development of new molecular syndromic IVD tests and test products, and overseeing the development of automated, high-throughput systems through the customisation of commercially available instruments.

*“After an extensive search process, we are delighted to have been able to secure someone of Dr Pedersen’s calibre for the business critical role of Genetic Signature’s Chief Technology Officer” said **Allison Rossiter, CEO of Genetic Signatures**. “Her extensive and in-depth experience in all aspects of developing commercially sound molecular IVD products will be invaluable for the Company. On behalf of the Board and the entire Genetic Signatures team, I would also like to thank Subita Sudershana, for her passion, drive and leadership as interim CTO for the past seven months.”*

– END –

Announcement authorised by Genetic Signatures’ Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter

Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann

Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures' proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.